The primary objectives are to:
1. To determine whether MIB-626, after its daily oral administration, penetrates the
blood-brain barrier in humans by measuring the cerebrospinal fluid (CSF) concentrations
of MIB-626 and its key metabolites, nicotinamide (NAM), NR, 2-PY, and MeNAM at baseline
and on day 90 at steady state.
2. To evaluate whether oral MIB-626 administration engages the sirtuin-NAD pathway by
determining the abundance of NAD (a SIRT1 substrate) in the brain using ultra-high field
7T magnetic resonance spectroscopy and in peripheral blood mononuclear cells using a
validated LC-MS/MS assay.
3. To determine whether MIB-626 alters the circulating biomarkers of aging that the
geroscience experts have recommended (HbA1C, IGF1, T3, IL6, TNF, and urinary
F2-isoprostane).